Mark Rodgers
Research Fellow
Email: mark.rodgers@york.ac.uk
Tel: 01904 321086
Fax: 01904 321041
Mark has a BSc in Psychology and an MSc in Health Sciences. Before joining CRD as a reviewer, he had worked on projects ranging from facial processing abilities in autism to the labour market discrimination of deaf and hearing-impaired adults. He has also worked in the field of health policy research and is interested in the impact of political issues on health care research.
Selected publications
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Sutton A, Sculpher M, Woolacott N. Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2010;15(10)
Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M. Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal. Pharmacoeconomics. 2010; 28(5):351-62
Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Health Technol Assess. 2010;15(Suppl 1):1-12